Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma
: results of the randomized phase III ECOG1496 study.
This report provides comprehensive information on the therapeutic development for Indolent Lymphoma
, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
"It is important to explore the potential of this medicine in other types of blood cancer, and our broad development program includes studies in aggressive and indolent lymphoma
that compare GA101with MabThera/Rituxan."
A clinical analysis of two indolent lymphoma
entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories)--a Southwest Oncology Group study.
"We now look forward to the results of our AUGMENT study, which is evaluating this important regimen in previously treated patients with indolent lymphomas
. These studies support our ongoing efforts to develop a portfolio of novel treatments for lymphoma." REVLIMID alone or in combination with rituximab is not approved for use in follicular lymphoma in any country.